SG Americas Securities LLC Decreases Holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART)

SG Americas Securities LLC decreased its holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 58.2% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 28,211 shares of the life sciences company’s stock after selling 39,260 shares during the period. SG Americas Securities LLC’s holdings in Integra LifeSciences were worth $513,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the business. Capital Research Global Investors grew its stake in shares of Integra LifeSciences by 37.7% during the first quarter. Capital Research Global Investors now owns 5,918,981 shares of the life sciences company’s stock valued at $209,828,000 after buying an additional 1,621,655 shares during the last quarter. Boston Partners bought a new position in Integra LifeSciences during the 1st quarter worth approximately $19,383,000. Cooke & Bieler LP increased its stake in Integra LifeSciences by 12.4% in the 2nd quarter. Cooke & Bieler LP now owns 3,514,281 shares of the life sciences company’s stock worth $102,406,000 after purchasing an additional 388,710 shares during the period. D. E. Shaw & Co. Inc. lifted its position in Integra LifeSciences by 64.6% in the second quarter. D. E. Shaw & Co. Inc. now owns 855,352 shares of the life sciences company’s stock valued at $24,925,000 after purchasing an additional 335,557 shares during the last quarter. Finally, Systematic Financial Management LP boosted its stake in shares of Integra LifeSciences by 540.6% during the second quarter. Systematic Financial Management LP now owns 397,474 shares of the life sciences company’s stock valued at $11,582,000 after purchasing an additional 335,424 shares during the period. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently commented on IART. Citigroup decreased their target price on shares of Integra LifeSciences from $20.00 to $16.00 and set a “sell” rating on the stock in a research note on Tuesday, October 1st. Bank of America lowered their price objective on shares of Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a research note on Monday, October 7th. Truist Financial cut their target price on Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a research note on Monday. Morgan Stanley upped their price target on Integra LifeSciences from $24.00 to $27.00 and gave the company an “underweight” rating in a research report on Monday, July 15th. Finally, BTIG Research upgraded Integra LifeSciences from a “sell” rating to a “neutral” rating in a research report on Monday, October 7th. Three investment analysts have rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, Integra LifeSciences presently has a consensus rating of “Hold” and an average target price of $26.50.

Integra LifeSciences Trading Up 1.5 %

NASDAQ:IART opened at $19.51 on Wednesday. Integra LifeSciences Holdings Co. has a one year low of $16.81 and a one year high of $45.42. The company’s 50-day simple moving average is $19.15 and its 200 day simple moving average is $25.76. The firm has a market capitalization of $1.54 billion, a P/E ratio of 39.02, a PEG ratio of 0.62 and a beta of 1.09. The company has a debt-to-equity ratio of 1.17, a current ratio of 3.39 and a quick ratio of 2.10.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Monday, July 29th. The life sciences company reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.62 by $0.01. Integra LifeSciences had a return on equity of 14.07% and a net margin of 1.51%. The company had revenue of $418.20 million during the quarter, compared to analyst estimates of $413.07 million. During the same quarter last year, the company earned $0.71 EPS. The firm’s revenue for the quarter was up 9.7% on a year-over-year basis. As a group, analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current fiscal year.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.